Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Liu, Yarong ^a   Fang, Jinxu ^a   Joo, Kye Il ^a   Wong, Michael K ^b   Wang, Pin ^a,c  

^a University of Southern California   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DOXORUBICIN PLUS PACLITAXEL; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CROSS LINKING; CROSSLINKED MULTILAMELLAR LIPOSOMAL VESICLE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG RETENTION; DRUG STABILITY; FEMALE; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; TUMOR CELL; TUMOR RESISTANCE; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; MELANOMA, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; P-GLYCOPROTEINS; PACLITAXEL;

EID: 84908123372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110611     Document Type: Article

References (37)

1. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
2. Teicher BA (2009) Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol: 1665-1673.
3. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10: 147-156.
4. Schöndorf T, Kurbacher C, Göhring U, Benz C, Becker M, et al. (2002) Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 22: 2199-2203.
5. Lespine A, Ménez C, Bourguinat C, Prichard RK (2012) P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist 2: 230-270.
6. Chen Y, Bathula SR, Li J, Huang L (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285: 22639-22650.
7. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, et al. (2005) Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 11: 523-530.
8. Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, et al. (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134: 597-607.
9. Liu Y, Rohrs J, Wang P (2014) Development and challenges of nanovectors in gene therapy. Nano LIFE 4: 1441007.
10. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat biotechnol 27: 659-666.
11. Calabrò F, Lorusso V, Rosati G, Manzione L, Frassinet iL, et al. (2009) Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115: 2652-2659.
12. Mamounas EP, Sledge GW Jr (2001) Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 28: 24-31.
13. Dean-Colomb W, Esteva F (2008) Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 35(2 Suppl 2): S31-38.
14. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, et al. (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26: 44-53.
15. Kataja V, Castiglione M (2008) ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(2 suppl): ii11-ii13.
16. Grasselli G, Viganò L, Capri G, Locatelli A, Tarenzi E, et al. (2001) Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with meta-static breast cancer. J Clin Oncol 19: 2222-2231.
17. Gustafson DL, Andrea L Merz, Long ME (2005) Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Letters 220: 161-169.
18. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, et al. (2006) Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 116: 150-158.
19. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, et al. (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436: 568-572.
20. Wang H, Zhao Y, Wu Y, Hu Y-l, Nan K, et al. (2011) Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32: 8281-8290.
21. Gao H, Zhang Z, Yu Z, He Q (2014) Cell-penetrating peptide based intelligent liposomal systems for enhanced drug delivery. Curr Pharm Biotechnol 15: 210-219.
22. Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, et al. (2013) Selective tumor cell targeting by the disaccharide moiety of bleomycin. J Am Chem Soc 135: 2883-2886.
23. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316.
24. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171.
25. Dobson PD, Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-210.
26. Hillaireau H, Couvreur P (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mo Life Sci 66: 2873-2896.
27. Sahay G, Alakhova DY, Kabanov AV (2010) Endocytosis of nanomedicines. J Control Release 145: 182-195.
28. Torchilin VP (2005) Recent Advances with Liposomes as Pharmaceutical Carriers. Nat Rev Drug Discov 4: 145-160.
29. Liu Y, Ji M, Wong MK, Joo K-I, Wang P (2013) Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. BioMed Research International 2013: 378380.
30. Joo K, Xiao L, Liu S, Liu Y, Lee C, et al. (2013) Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials 34: 3098-3109.
31. Liu Y, Fang J, Kim Y-J, Wong MK, Wang P (2014) Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharmaceutics 11: 1651-1661.
32. Lee B, French K, Zhuang Y, Smith C (2003) Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res 14: 49-60.
33. Goutelle S, Maurin M, Rougier l, Barbaut X, Bourguignon L, et al. (2008) The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 22: 633-648.
34. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762-766.
35. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, et al. (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61: 3-13.
36. Rahman AM, Yusuf SW, Ewer MS (2007) Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine 2: 567-583.
37. Bird B, Swain S (2008) Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 14: 14-24.